Get started today

Cannabinoids and Cardiovascular Disease

Presented by Dr Philip Blair, MD

About this module:

Cardiovascular disease is a leading cause of morbidity and mortality. There is evidence that the endocannabinoid system is involved in pathogenic conditions of the heart. In this presentation, we explore how the endocannabinoid system is involved in cardiovascular disease, and the evidence that CBD and THC may be useful in treating different cardiovascular conditions. This presentation assumes an understanding of the endocannabinoid system and how CBD and THC work.

This presentation is pitched at the level of healthcare practitioners and those with a background in biomedical sciences. 
Learning Outcomes

At the end of this module, learners will be able to:

  • Describe changes in the endocannabinoid system that can occur in cardiovascular disease.
  • Explain the role of mitochondria and mitochondrial cannabinoid receptors in the heart.
  • Describe the potential mechanisms of action of CBD in cardiovascular conditions.
  • Argue the evidence base for use of CBD in the treatment of cardiovascular conditions.
  • Explain whether there is any evidence for detrimental effects of CBD or THC on the heart.

Dr Philip Blair, MD

Dr. Philip Blair, MD, (Colonel, US Army, retired) is a Family Physician and consultant in disease management in the Northwest USA. He graduated from West Point in 1972, attended the University of Miami School of Medicine, training as an Army Family Physician and serving as a combat physician in the first Gulf War. After medical assignments in three continents and 29 years in uniform, he retired from the Army and has been consulting on complex disease management since 2000.

Dr. Blair has been studying, treating, and lecturing about the human body’s natural endocannabinoid system (ECS) since 2014. His goal is to restore health and performance by enhancing the ECS using diet, exercise, appropriate medications and non-psychoactive therapies.
Created with